NCD On ESAs In Renal Setting Opposed By Physicians, Patients, And Amgen

Amgen is being joined by industry and patient advocacy groups in calling on CMS to back away from considering a national coverage determination for Medicare Part B reimbursement of erythropoiesis-stimulating agents in the renal setting until data suggests a need for closer examination